Revolution Medicines (RVMD) Non Operating Income (2019 - 2026)

Revolution Medicines' Non Operating Income history runs 8 years deep, the most recent figure standing at -$8.6 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 131.43% year-over-year to -$8.6 million in Q1 2026; TTM through Mar 2026 was $15.1 million, a 83.4% decrease from a year earlier, with the FY2025 full-year figure at $51.1 million, down 42.41% from the prior year.
• Non Operating Income fell to -$8.6 million in Q1 2026 per RVMD's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Non Operating Income topped out at $27.3 million in Q1 2025 and bottomed at -$8.6 million in Q1 2026.
• The 5-year median for Non Operating Income is $10.5 million (2023), against an average of $11.0 million.
• Across the five-year window, Non Operating Income jumped 2237.42% in 2023 and slumped 131.43% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $5.1 million in 2022, then surged by 270.08% to $18.8 million in 2023, then advanced by 11.7% to $21.0 million in 2024, then plunged by 115.56% to -$3.3 million in 2025, then sank by 163.14% to -$8.6 million in 2026.
• Per Business Quant, the three latest RVMD Non Operating Income figures stand at -$8.6 million (Q1 2026), -$3.3 million (Q4 2025), and $10.1 million (Q3 2025).